# reload+after+2024-01-20 18:47:02.414424
address1§110 East 59th Street
city§New York
state§NY
zip§10022
country§United States
phone§212 883 0200
website§https://www.royaltypharma.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Pablo Gerardo Legorreta', 'age': 59, 'title': 'Founder, Chairman of the Board & CEO', 'yearBorn': 1964, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Terrance P. Coyne', 'title': 'Executive VP & CFO', 'fiscalYear': 2022, 'totalPay': 4350000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. George Wingate Lloyd', 'age': 64, 'title': 'Executive VP of Investments & Chief Legal Officer', 'yearBorn': 1959, 'fiscalYear': 2022, 'totalPay': 4350000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Christopher  Hite', 'age': 56, 'title': 'Vice Chairman & Executive VP', 'yearBorn': 1967, 'fiscalYear': 2022, 'totalPay': 4350000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Marshall  Urist M.D., Ph.D.', 'title': 'Executive VP and Head of Research & Investments', 'fiscalYear': 2022, 'totalPay': 4350000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Arthur R. McGivern J.D.', 'title': 'Executive Vice President of Investments & General Counsel', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Ashwin  Pai M.D.', 'title': 'Executive Vice President of Investments', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Kristin  Stafford', 'age': 41, 'title': 'Senior VP & Chief Accounting Officer', 'yearBorn': 1982, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Eric  Schneider', 'title': 'Senior VP & Chief Technology Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. James Folmar Reddoch Ph.D.', 'age': 53, 'title': 'Executive VP of Investments & Chief Scientific Officer', 'yearBorn': 1970, 'fiscalYear': 2022, 'totalPay': 3395000, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§5
boardRisk§5
compensationRisk§3
shareHolderRightsRisk§6
overallRisk§4
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
dividendRate§0.8
dividendYield§0.0291
exDividendDate§1700092800
payoutRatio§2.0256
beta§0.424
priceToSalesTrailing12Months§7.0838842
currency§USD
dateShortInterest§1702598400
forwardEps§3.95
pegRatio§2.01
exchange§NMS
quoteType§EQUITY
shortName§Royalty Pharma plc
longName§Royalty Pharma plc
firstTradeDateEpochUtc§1592314200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§39335a92-43fb-3820-bdda-2f1c7ffd138d
gmtOffSetMilliseconds§-18000000
targetHighPrice§60.0
targetLowPrice§37.0
targetMeanPrice§46.57
targetMedianPrice§45.0
recommendationMean§1.7
recommendationKey§buy
numberOfAnalystOpinions§7
quickRatio§13.459
earningsGrowth§-0.507
grossMargins§0.59298
ebitdaMargins§0.43743
trailingPegRatio§None
